# EDGAR Filing Document

**Accession Number:** 0000049071
**File Stem:** 0000049071-26-000021
**Filing Date:** 2026-4
**Character Count:** 121599
**Document Hash:** 7ff29ec14de4ad2b3955aa390da71883
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0000049071-26-000021.hdr.sgml**: 20260429

**ACCESSION NUMBER**: 0000049071-26-000021

**CONFORMED SUBMISSION TYPE**: 8-K

**PUBLIC DOCUMENT COUNT**: 17

**CONFORMED PERIOD OF REPORT**: 20260429

**ITEM INFORMATION**: Results of Operations and Financial Condition

**ITEM INFORMATION**: Regulation FD Disclosure

**ITEM INFORMATION**: Financial Statements and Exhibits

**FILED AS OF DATE**: 20260429

**DATE AS OF CHANGE**: 20260429

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** HUMANA INC
- **CENTRAL INDEX KEY:** 0000049071
- **STANDARD INDUSTRIAL CLASSIFICATION:** HOSPITAL & MEDICAL SERVICE PLANS [6324]
- **ORGANIZATION NAME:** 02 Finance
- **EIN:** 610647538
- **STATE OF INCORPORATION:** DE
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 8-K
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-05975
- **FILM NUMBER:** 26910298

**BUSINESS ADDRESS:**
- **STREET 1:** 101 E. MAIN STREET
- **CITY:** LOUISVILLE
- **STATE:** KY
- **BUSINESS PHONE:** 5025801000

**MAIL ADDRESS:**
- **STREET 1:** 101 E. MAIN STREET
- **CITY:** LOUISVILLE
- **STATE:** KY

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** EXTENDICARE INC
- **DATE OF NAME CHANGE:** 19740404

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** HERITAGE HOUSE OF AMERICA INC
- **DATE OF NAME CHANGE:** 19671129

?xml version='1.0' encoding='ASCII'? hum-20260429

**UNITED STATES**

**SECURITIES AND EXCHANGE COMMISSION**

**Washington, DC 20549**

**FORM 8-K** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

**CURRENT REPORT**

**Pursuant to Section 13 or 15(d) of the**

**Securities Exchange Act of 1934**

**Date of Report (Date of earliest event reported): April 29, 2026 (April 29, 2026)**

**Humana Inc.** 

**(Exact name of registrant as specified in its charter)**

---

| | | |
|:---|:---|:---|
| **Delaware** | **1-5975** | **61-0647538** |
| **(State or other jurisdiction of incorporation)** | **(Commission File Number)** | **(IRS Employer Identification No.)** |

---

**101 East Main Street, Louisville, KY 40202** 

**(Address of principal executive offices, including zip code)**

**502-580-1000** 

**(Registrant's telephone number, including area code)**

**(Former name or former address, if changed since last report)**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (*see* General Instruction A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

---

| | | |
|:---|:---|:---|
| **<u>Title of each class</u>** | **<u>Trading Symbol(s)</u>** | **<u>Name of each exchange on which registered</u>** |
| Common Stock | HUM | New York Stock Exchange |

---

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (17 CFR §230.405) or Rule 12b-2 of the Securities Exchange Act of 1934 (17 CFR §240.12b-2).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

------

**Item 2.02&nbsp;&nbsp;&nbsp;&nbsp;Results of Operations and Financial Condition.**

**Item 7.01&nbsp;&nbsp;&nbsp;&nbsp;Regulation FD Disclosure.**

Humana Inc. (the "Company") issued a press release this morning reporting financial results for the quarter ended March 31, 2026, and posted a detailed earnings release related to the same period to the Investor Relations portion of the Company's website at <u>www.humana.com</u>. A copy of each release is attached hereto as Exhibit 99.1 and Exhibit 99.2, respectively, and each release is incorporated herein by reference. Additionally, a copy of management's prepared remarks on the Company's financial results for the quarter ended March 31, 2026 and expectations for future earnings, is attached hereto as Exhibit 99.3, and incorporated herein by reference.

**Item 9.01&nbsp;&nbsp;&nbsp;&nbsp;Financial Statements and Exhibits.**

(d)Exhibits:

---

| | |
|:---|:---|
| **Exhibit No.** | **Description** |
| 99.1 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Press Release](hum-2026q1xex99x1briefxapr.htm)</u> |
| 99.2 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Earnings Release and Statistical Pages](hum-2026q1xex99x2detailedx.htm)</u> |
| 99.3 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;<u>[Prepared Management Remarks](a1q2026humanaincpostedrema.htm)</u> |
| 104 | &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cover Page Interactive Data File (embedded within the Inline XBRL document) |

---

------

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned hereunto duly authorized.

---

| | |
|:---|:---|
| **HUMANA INC.** | **HUMANA INC.** |
| **BY:** | **/s/ John-Paul W. Felter** |
| | **John-Paul W. Felter** |
| | **Senior Vice President, Chief Accounting Officer & Controller** |
| | **(Principal Accounting Officer)** |

---

Dated: April 29, 2026

## Exhibit 99.1

---

| | |
|:---|:---|
| **n e w s** r e l e a s e | **Exhibit 99.1**<br>Humana Inc.<br>101 East Main Street<br>P.O. Box 1438<br>Louisville, KY 40202<br><u>http://www.humana.com</u> |

---

FOR MORE INFORMATION CONTACT:

---

| | |
|:---|:---|
| Lisa Stoner<br>Humana Investor Relations<br>(502) 580-2652<br>e-mail: LStamper@humana.com | ![humanalogoa05a.jpg](humanalogoa05a.jpg) |

---

Mark Taylor

Humana Corporate Communications

(317) 753-0345

e-mail: MTaylor108@humana.com

**Humana Reports First Quarter 2026 Financial Results;** 

**Affirms Full Year 2026 Adjusted Financial Guidance** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Reports 1Q26 earnings per share (EPS) of $9.83 on a GAAP basis, Adjusted EPS of $10.31; at the high end of the company's guidance of approximately 110 percent to 115 percent of full year (FY) 2026 Adjusted EPS

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 1Q26 Insurance segment GAAP benefit ratio of 89.4 percent, slightly favorable to management's guidance of 'just under 90 percent'; affirms FY 2026 Insurance segment benefit ratio guidance of 92.75 percent, plus or minus 25 basis points

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Affirms Adjusted FY 2026 GAAP EPS guidance of 'at least $9.00'; while revising GAAP EPS guidance to 'at least $8.36' from the previous estimate of 'at least $8.89'

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Affirms FY 2026 individual Medicare Advantage (MA) membership growth of 'approximately 25 percent' over 2025; driven by new sales and improved retention from the company's customer-led benefit strategy and changes to its customer service approach

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Continued execution of strategic growth initiatives and integration of new contracts within CenterWell and state-based contracts businesses, respectively, to expand the company's national footprint

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Sequential growth of 110,500 patients, or over 22 percent, in CenterWell Senior Primary Care, including approximately 59,000 patients and 54 centers associated with the recently completed acquisition of MaxHealth

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ CenterWell Pharmacy and Cost Plus partnering to develop new, end-to-end employer prescription drug solutions

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ 1Q26 state-based contracts membership growth of approximately 50,000, driven by the start of programs in Michigan, Illinois, and South Carolina

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Publishes prepared management remarks to Investor Relations page of www.humana.com ahead of this morning's 8:00 a.m. ET question and answer session to discuss its financial results for the quarter and expectations for future earnings

**LOUISVILLE, KY (April 29, 2026)** – Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share (EPS) for the quarter ended March 31, 2026 (1Q26) versus the quarter ended March 31, 2025 (1Q25) as noted in the tables below.

------

---

| | | |
|:---|:---|:---|
| **Consolidated income before income taxes and equity in net losses (pretax results)**<br>*in millions* | **1Q26 (a)** | **1Q25 (a)** |
| **Generally Accepted Accounting Principles (GAAP)** | **$1595** | $1691 |
| Amortization associated with identifiable intangibles | **11** | 15 |
| Put/call valuation adjustments associated with company's non-consolidating minority interest investments | **(34)** | 163 |
| Value creation initiatives | **98** | 24 |
| **Adjusted (non-GAAP)** | **$1670** | $1893 |

---

---

| | | |
|:---|:---|:---|
| **Diluted earnings per share (EPS)** | **1Q26 (a)** | **1Q25 (a)** |
| **GAAP** | **$9.83** | $10.30 |
| Amortization associated with identifiable intangibles | **0.09** | 0.12 |
| Put/call valuation adjustments associated with company's non-consolidating minority interest investments | **(0.28)** | 1.35 |
| Value creation initiatives | **0.81** | 0.20 |
| Tax impact of non-GAAP adjustments | **(0.14)** | (0.39) |
| **Adjusted (non-GAAP)** | **$10.31** | $11.58 |

---

*Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as reconciliations.*

Please refer to the tables above, as well as the consolidated and segment highlight sections in the detailed earnings release for additional discussion of the factors impacting the year-over-year comparisons.

"We've had a solid start to the year and feel good about how our operating execution and transformation initiatives are setting us up for the future," said Humana President and CEO Jim Rechtin. "We continue to make progress where it counts for customers - quality experience and outstanding care."

***<u>Insurance Leadership Transition Update (Announced December 2025)</u>***

The company today confirmed that George Renaudin, Insurance Segment President, will retire effective June 29, 2026, consistent with the timeline previously communicated. Until that date, Renaudin will focus primarily on the annual Medicare Advantage bid process, while Aaron Martin, currently President of Medicare Advantage, will begin leading the day-to-day management of the Insurance Segment. Upon Renaudin's retirement, Martin will formally assume the role of Insurance Segment President and Renaudin will serve as a strategic advisor to the company through at least the end of 2026. The company also confirmed that 30-year industry veteran John Barger will begin leading Medicare Advantage operations effective immediately and will formally assume the role of President of Medicare Advantage upon Renaudin's retirement.

***<u>FY 2026 Earnings Guidance</u>***

Humana revises its GAAP EPS guidance for the year ending December 31, 2026 (FY 2026) to 'at least $8.36' from 'at least $8.89', while affirming its Adjusted EPS guidance of 'at least $9.00'. The FY 2026 Adjusted EPS guidance anticipates a year-over-year decline as a result of the Star Ratings headwind for Bonus Year (BY) 2026, net of mitigation.

------

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;<br>**Diluted earnings per share (a)** | **FY 2026<br> Guidance** | **FY 2025** |
| **GAAP** | **at least $8.36** | $9.84 |
| Amortization associated with identifiable intangibles | **0.30** | 0.42 |
| Put/call valuation adjustments associated with the company's non-consolidating minority interest investments (b) | **(0.28)** | 4.25 |
| Value creation initiatives (b) | **0.81** | 3.72 |
| Impact of exit of employer group commercial medical products business (b) | **—** | (0.52) |
| Settlement of certain litigation expenses (b) | **—** | 0.13 |
| Loss on sale of business (b) | **—** | 0.55 |
| Impairment charges (b) | **—** | 2.09 |
| Cumulative net tax impact | **(0.19)** | (3.34) |
| **Adjusted (non-GAAP) – FY 2026 projected (b); FY 2025 reported** | **at least $9.00** | $17.14 |

---

*Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as additional reconciliations.*

***<u>Detailed Press Release</u>***

Humana's full earnings press release, including the statistical pages, has been posted to the company's Investor Relations site and may be accessed at https://humana.gcs-web.com/ or via a current report on Form 8-K filed by the company with the Securities and Exchange Commission this morning (available at www.sec.gov or on the company's website).

***<u>Conference Call</u>***

Humana will host a live question-and-answer session for analysts at 8:00 a.m. Eastern time today to discuss its financial results for the quarter and the company's expectations for future earnings. In advance of the question-and-answer session, Humana will post prepared management remarks to the Quarterly Results section of its Investor Relations page (https://humana.gcs-web.com/financial-information/quarterly-results).

A webcast of the 1Q26 earnings call may be accessed via Humana's Investor Relations page at https://humana.gcs-web.com/.

If you anticipate asking a question during the question-and-answer session, please register in advance at this link - https://register-conf.media-server.com/register/BId1413c4c078343e28841e18c372f7b58.

Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID.

The company suggests participants listening via the web or the conference call sign in or dial in at least 15 minutes in advance of the call. For those unable to participate in the live event, the virtual presentation archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page at https://humana.gcs-web.com/, approximately two hours following the live webcast.

***<u>Footnotes</u>***

The company has included financial measures throughout this earnings release that are not in accordance with GAAP. Management believes that these measures, when presented in conjunction with the corresponding GAAP measures, provide a comprehensive perspective to more accurately compare and analyze the company's core operating performance over time. Consequently, management uses these non-GAAP (Adjusted) financial measures as consistent indicators of the company's core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Non-GAAP (Adjusted) financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP. The company's non-GAAP measures are not intended to normalize earnings, eliminate volatility, or represent future performance. Non-GAAP measures are subject to inherent limitations and may differ from similarly titled measures used by other companies. All financial measures in this earnings release are in accordance with GAAP unless otherwise indicated. Please refer to the

------

footnotes for a detailed description of each item adjusted out of GAAP financial measures to arrive at non-GAAP (Adjusted) financial measures.

(a) For the periods covered in this earnings release, the following items are excluded from the non-GAAP financial measures described above, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Amortization associated with identifiable intangibles -** Since amortization varies based on the size and timing of acquisition activity, management believes the exclusion of this non-cash expense provides a more consistent and uniform indicator of performance from period to period. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results, EPS, and Insurance and CenterWell segments' income from operations. The table below discloses respective period amortization expense for each segment:

---

| | | |
|:---|:---|:---|
| **Amortization** <br>*(in millions)* | **1Q26** | **1Q25** |
| Insurance segment | **$4** | $4 |
| CenterWell segment | **$7** | $11 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Put/call valuation adjustments associated with the company's non-consolidating minority interest investments -** These non-cash amounts are the result of fair value measurements associated with the company's primary care strategic partnership and are unrelated to the company's core business performance. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results and EPS.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Value creation initiatives -** These charges relate to the company's multi-year transformation program, as approved by management with defined scope and milestones. The intent of the program is to re-align the company's cost structure, operating model, and technology footprint with evolving market conditions. These costs primarily include severance and associate exit costs, asset impairments, and external consulting expenses incurred to execute the program. These charges were recorded at the corporate level and not allocated to the segments. The company has consistently applied this adjustment across all periods. For all periods shown within this earnings release, GAAP measures affected in this release include consolidated pretax results, EPS, and the consolidated operating cost ratio.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Cumulative net tax impact -** This adjustment represents the cumulative net impact of the corresponding tax benefit or expense at the applicable marginal rate related to the aforementioned items excluded from the applicable GAAP measures. For FY 2025, the tax adjustment reflects the impact of the loss on sale of business, which exceeded the book loss. The related tax benefit from the loss on sale of business is realizable via capital loss carryback. The tax impact of the aforementioned items differs from the statutory rates due to jurisdictional mix, limitations on deductibility, and other factors. The cumulative tax impact is not intended to represent a normalized effective tax rate or expected future tax outcomes. For all periods presented in this earnings release, EPS is the sole GAAP measure affected.

The following adjustments impact only the FY 2025 GAAP EPS shown within this release on page 2.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***•* Impact of exit of employer group commercial medical products business -** These amounts relate to activity from the exit of the employer group commercial medical products business as announced by Humana on February 23, 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Settlement of certain litigation expenses -** These charges relate to expenses the company recognized in connection with a discrete legal matter. The nature and magnitude of this settlement are not indicative of the company's ongoing operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Loss on sale of business -** This discrete disposition is not part of the company's ordinary course operations and the impacts recognized from the disposal do not reflect core operational performance. The loss primarily reflects the difference between the carrying value and proceeds at the time of sale.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Impairment charges -** The company recognized non-cash impairment charges related to certain indefinite-lived intangible assets based on the company's estimate of future financial performance in certain state markets. Additionally, the company recognized non-cash impairment charges in the fourth quarter of 2025 related to a discrete joint-venture investment for which the company held minority ownership interests that were deemed to be unrecoverable based on recent market activity. These charges were recorded at the corporate level and not allocated to the segments.

In addition to the reconciliations shown on page 2 of this release, the following are reconciliations of GAAP to Adjusted (non-GAAP) measures described above and disclosed within this earnings release:

------

***<u>Operating cost ratio</u>***

---

| | | |
|:---|:---|:---|
| **CONSOLIDATED<br>Operating cost ratio** | **1Q26** | **1Q25** |
| **GAAP** | **10.2%** | 10.6% |
| Value creation initiatives | **(0.2)%** | (0.1)% |
| **Adjusted (non-GAAP)** | **10.0%** | 10.5% |

---

***<u>Insurance Segment - Income from operations</u>***

---

| | | |
|:---|:---|:---|
| **INSURANCE SEGMENT**<br>**Income from operations** <br>*(in millions)* | **1Q26** | **1Q25** |
| **GAAP** | **$1435** | $1574 |
| Amortization associated with identifiable intangibles | **4** | 4 |
| **Adjusted (non-GAAP)** | **$1439** | $1578 |

---

(b) FY 2026 GAAP EPS guidance and FY 2026 Adjusted (non-GAAP) EPS guidance exclude the impact of future value changes to items that have not yet been recognized and cannot currently be reasonably estimated at this time.

**<u>Cautionary Statement</u>**

This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of Humana's executive officers, the words or phrases like "expects," "believes," "anticipates," "assumes," "intends," "likely will result," "estimates," "projects" or variations of such words and similar expressions are intended to identify such forward-looking statements.

These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the "Risk Factors" section of the company's SEC filings, a summary of which includes but is not limited to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If Humana does not design and price its products properly and competitively, if the premiums Humana receives are insufficient to cover the cost of healthcare services delivered to its members, if the company is unable to implement clinical initiatives to provide a better healthcare experience for its members, lower costs and appropriately document the risk profile of its members, or if its estimates of benefits expense are inadequate, Humana's profitability could be materially adversely affected. Humana estimates the costs of its benefit expense payments, and designs and prices its products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. The company continually reviews estimates of future payments relating to benefit expenses for services incurred in the current and prior periods and makes necessary adjustments to its reserves, including premium deficiency reserves, where appropriate. These estimates involve extensive judgment, and have considerable inherent variability because they are extremely sensitive to changes in claim payment patterns and medical cost trends. Accordingly, Humana's reserves may be insufficient.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If Humana fails to effectively implement its operational and strategic initiatives, including its Medicare initiatives, which are of particular importance given the concentration of the company's revenues in these products, state-based contract strategy, the growth of its CenterWell business, and its integrated care delivery model, the company's business may be materially adversely affected.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The number of Humana's Medicare Advantage plans rated 4-star or higher significantly declined in 2025. Humana filed a lawsuit seeking to set aside and vacate the 2025 Star Ratings of its Medicare Advantage plans, and on October 14, 2025, the Court issued a decision rejecting Humana's challenge. Although the company has appealed that decision, there can be no assurances that it will ultimately prevail in the lawsuit.

------

If the company is not successful, the decline in Star Ratings will negatively impact its 2026 quality bonus payments from CMS and may also significantly adversely affect the company's revenues, operating results, and cash flows. In addition, there can be no assurances the company will be successful in maintaining or improving its Star Ratings in future years.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Humana is involved in various legal actions, or disputes that could lead to legal actions (such as, among other things, provider contract disputes and qui tam litigation brought by individuals on behalf of the government), governmental and internal investigations, and routine internal review of business processes any of which, if resolved unfavorably to the company, could result in substantial monetary damages or changes in its business practices. Increased litigation and negative publicity could also increase the company's cost of doing business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• As a government contractor, Humana is exposed to risks that may materially adversely affect its business or its willingness or ability to participate in government healthcare programs including, among other things, loss of material government contracts; governmental audits and investigations; potential inadequacy of government determined payment rates; potential restrictions on profitability, including by comparison of profitability of the company's Medicare Advantage business to non-Medicare Advantage business; or other changes in the governmental programs in which Humana participates. Changes to the risk-adjustment model utilized by CMS to adjust premiums paid to Medicare Advantage plans or retrospective recovery by CMS of previously paid premiums as a result of the final rule related to the risk adjustment data validation audit methodology published by CMS on January 30, 2023 (Final RADV Rule), which Humana believes fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act due to its failure to include a "Fee for Service Adjuster" could have a material adverse effect on the company's operating results, financial position and cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Humana's business activities are subject to substantial government regulation. New laws or regulations, or legislative, judicial, or regulatory changes in existing laws or regulations or their manner of application could increase the company's cost of doing business and have a material adverse effect on Humana's results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting the company's ability to expand into new markets, increasing the company's medical and operating costs by, among other things, requiring a minimum benefit ratio on insured products, lowering the company's Medicare payment rates and increasing the company's expenses associated with a non-deductible health insurance industry fee and other assessments); the company's financial position (including the company's ability to maintain the value of its goodwill); and the company's cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Humana's failure to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on the company's results of operations, financial position, and cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If Humana fails to develop and maintain satisfactory relationships with the providers of care to its members, the company's business may be adversely affected.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Humana faces significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to the Company's success, and its failure to do so could adversely affect the Company's businesses, operating results and/or future performance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Humana's pharmacy business is highly competitive and subjects it to regulations and supply chain risks in addition to those the company faces with its core health benefits businesses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes in the prescription drug industry pricing benchmarks may adversely affect Humana's financial performance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Humana's ability to obtain funds from certain of its licensed subsidiaries is restricted by state insurance regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Downgrades in Humana's debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Volatility or disruption in the securities and credit markets may significantly and adversely affect the value of our investment portfolio and the investment income that we derive from this portfolio.

In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.

Humana advises investors to read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Form 10-K for the year ended December 31, 2025; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Form 8-Ks filed during 2026.

***<u>About Humana</u>***

Humana (NYSE: HUM) is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.

## Exhibit 99.2

**n e w s r e l e a s e**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;

<br>**Exhibit 99.2**<br>

Humana Inc.101 East Main StreetP.O. Box 1438Louisville, KY 40202<u>http://www.humana.com</u>

---

| | |
|:---|:---|
| FOR MORE INFORMATION CONTACT: | &nbsp;&nbsp;&nbsp;&nbsp;![humanalogoa05a.jpg](humanalogoa05a.jpg) |

---

Lisa Stoner

Humana Investor Relations

(502) 580-2652

e-mail: LStamper@humana.com

Mark Taylor

Humana Corporate Communications

(317) 753-0345

e-mail: MTaylor108@humana.com

**Humana Reports First Quarter 2026 Financial Results;** 

**Affirms Full Year 2026 Adjusted Financial Guidance** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Reports 1Q26 earnings per share (EPS) of $9.83 on a GAAP basis, Adjusted EPS of $10.31; at the high end of the company's guidance of approximately 110 percent to 115 percent of full year (FY) 2026 Adjusted EPS

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 1Q26 Insurance segment GAAP benefit ratio of 89.4 percent, slightly favorable to management's guidance of 'just under 90 percent'; affirms FY 2026 Insurance segment benefit ratio guidance of 92.75 percent, plus or minus 25 basis points

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Affirms Adjusted FY 2026 GAAP EPS guidance of 'at least $9.00'; while revising GAAP EPS guidance to 'at least $8.36' from the previous estimate of 'at least $8.89'

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Affirms FY 2026 individual Medicare Advantage (MA) membership growth of 'approximately 25 percent' over 2025; driven by new sales and improved retention from the company's customer-led benefit strategy and changes to its customer service approach

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Continued execution of strategic growth initiatives and integration of new contracts within CenterWell and state-based contracts businesses, respectively, to expand the company's national footprint

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ Sequential growth of 110,500 patients, or over 22 percent, in CenterWell Senior Primary Care, including approximately 59,000 patients and 54 centers associated with the recently completed acquisition of MaxHealth

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ CenterWell Pharmacy and Cost Plus partnering to develop new, end-to-end employer prescription drug solutions

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;◦ 1Q26 state-based contracts membership growth of approximately 50,000, driven by the start of programs in Michigan, Illinois, and South Carolina

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Publishes prepared management remarks to Investor Relations page of www.humana.com ahead of this morning's 8:00 a.m. ET question and answer session to discuss its financial results for the quarter and expectations for future earnings

**LOUISVILLE, KY (April 29, 2026)** – Humana Inc. (NYSE: HUM) today reported consolidated pretax results and diluted earnings per share (EPS) for the quarter ended March 31, 2026 (1Q26) versus the quarter ended March 31, 2025 (1Q25) as noted in the tables below.

------

---

| | | |
|:---|:---|:---|
| **Consolidated income before income taxes and equity in net losses (pretax results)**<br>*in millions* | **1Q26 (a)** | **1Q25 (a)** |
| **Generally Accepted Accounting Principles (GAAP)** | **$1595** | $1691 |
| Amortization associated with identifiable intangibles | **11** | 15 |
| Put/call valuation adjustments associated with company's non-consolidating minority interest investments | **(34)** | 163 |
| Value creation initiatives | **98** | 24 |
| **Adjusted (non-GAAP)** | **$1670** | $1893 |

---

---

| | | |
|:---|:---|:---|
| **Diluted earnings per share (EPS)** | **1Q26 (a)** | **1Q25 (a)** |
| **GAAP** | **$9.83** | $10.30 |
| Amortization associated with identifiable intangibles | **0.09** | 0.12 |
| Put/call valuation adjustments associated with company's non-consolidating minority interest investments | **(0.28)** | 1.35 |
| Value creation initiatives | **0.81** | 0.20 |
| Tax impact of non-GAAP adjustments | **(0.14)** | (0.39) |
| **Adjusted (non-GAAP)** | **$10.31** | $11.58 |

---

*Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as reconciliations.*

Please refer to the tables above, as well as the consolidated and segment highlight sections that follow for additional discussion of the factors impacting the year-over-year comparisons.

"We've had a solid start to the year and feel good about how our operating execution and transformation initiatives are setting us up for the future," said Humana President and CEO Jim Rechtin. "We continue to make progress where it counts for customers - quality experience and outstanding care."

***<u>Insurance Leadership Transition Update (Announced December 2025)</u>***

The company today confirmed that George Renaudin, Insurance Segment President, will retire effective June 29, 2026, consistent with the timeline previously communicated. Until that date, Renaudin will focus primarily on the annual Medicare Advantage bid process, while Aaron Martin, currently President of Medicare Advantage, will begin leading the day-to-day management of the Insurance Segment. Upon Renaudin's retirement, Martin will formally assume the role of Insurance Segment President and Renaudin will serve as a strategic advisor to the company through at least the end of 2026. The company also confirmed that 30-year industry veteran John Barger will begin leading Medicare Advantage operations effective immediately and will formally assume the role of President of Medicare Advantage upon Renaudin's retirement.

***<u>FY 2026 Earnings Guidance</u>***

Humana revises its GAAP EPS guidance for the year ending December 31, 2026 (FY 2026) to 'at least $8.36' from 'at least $8.89', while affirming its Adjusted EPS guidance of 'at least $9.00'. The FY 2026 Adjusted EPS guidance anticipates a year-over-year decline as a result of the Star Ratings headwind for Bonus Year (BY) 2026, net of mitigation. Additional FY 2026 guidance points are included on page 12 of this earnings release.

------

---

| | | |
|:---|:---|:---|
| &nbsp;&nbsp;&nbsp;&nbsp;<br>**Diluted earnings per share (a)** | **FY 2026<br> Guidance** | **FY 2025** |
| **GAAP** | **at least $8.36** | $9.84 |
| Amortization associated with identifiable intangibles | **0.30** | 0.42 |
| Put/call valuation adjustments associated with the company's non-consolidating minority interest investments (b) | **(0.28)** | 4.25 |
| Value creation initiatives (b) | **0.81** | 3.72 |
| Impact of exit of employer group commercial medical products business (b) | **—** | (0.52) |
| Settlement of certain litigation expenses (b) | **—** | 0.13 |
| Loss on sale of business (b) | **—** | 0.55 |
| Impairment charges (b) | **—** | 2.09 |
| Cumulative net tax impact | **(0.19)** | (3.34) |
| **Adjusted (non-GAAP) – FY 2026 projected (b); FY 2025 reported** | **at least $9.00** | $17.14 |

---

*Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well*

*as reconciliations.*

***<u>Humana Consolidated Highlights</u>***

---

| | | |
|:---|:---|:---|
| **Humana Inc. Summary of Results**<br> *($ in millions, except per share amounts)* | **1Q26 (a)** | **1Q25 (a)** |
| Revenues | **$39648** | $32112 |
| Pretax results | **$1595** | $1691 |
| Pretax results - Adjusted (non-GAAP) | **$1670** | $1893 |
| EPS | **$9.83** | $10.30 |
| EPS - Adjusted (non-GAAP) | **$10.31** | $11.58 |
| Benefit ratio | **89.4%** | 87.0% |
| Operating cost ratio | **10.2%** | 10.6% |
| Operating cost ratio - Adjusted (non-GAAP) | **10.0%** | 10.5% |
| Operating cash flows | **$1254** | $331 |
| Parent company cash and short-term investments | **$111** | $1234 |
| Debt-to-total capitalization | **43.0%** | 42.8% |
| Days in Claims Payable (DCP) | **33.9** | 38.8 |

---

*Refer to the "Footnotes" section included herein for further explanation of disclosures for Adjusted (non-GAAP) financial measures, as well as reconciliations.*

**<u>Consolidated Revenues</u>**

The favorable year-over-year GAAP consolidated revenues comparison was primarily driven by the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• membership growth across the company's Medicare businesses in 2026,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• higher per member MA and stand-alone PDP premiums largely driven by an increase in MA benchmark funding from the Centers for Medicare and Medicaid Services (CMS) and the increased Part D direct subsidy as a result of the Inflation Reduction Act (IRA), and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• increased payor-agnostic client base across the CenterWell platform, partially offset by the final year of the v28 risk model revision phase-in.

------

These factors were partially offset by the previously disclosed BY 2026 Star Ratings headwind.

**<u>Consolidated Benefit Ratio</u>** 

The year-over-year increase in the GAAP consolidated benefit ratio primarily reflected the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the BY 2026 Star Ratings revenue headwind,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the effect of the individual MA membership growth during the most recent Annual Election Period (AEP) and Open Enrollment Period (OEP) as the new members, on average, run at a higher benefit ratio as compared to retained members (excluding the impact of the BY 2026 Star Ratings headwind), and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the anticipated lower favorable prior period medical claims reserve development (prior period development) in 1Q26. Prior period development was $389 million favorable in 1Q26 compared to $477 million favorable in 1Q25. This development does not directly correspond to the company's operating results as a portion is attributable to provider risk-sharing arrangements, which are accounted for separately based on contractual terms.

These factors were partially offset by the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 2026 individual MA pricing, inclusive of the MA funding environment (excluding the BY 2026 Star Ratings headwind) combined with the company's ongoing clinical excellence efforts, more than offsetting the assumption of claims trend (with largely stable benefits year over year), and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the benefit of the company's group MA recontracting efforts for the 2026 plan year.

**<u>Consolidated Operating Cost Ratio</u>**

The year-over-year improvement in the GAAP operating cost ratio from 1Q25 primarily resulted from the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• operating leverage associated with increased revenues from membership growth across the company's Medicare businesses in 2026 combined with an improved MA benchmark funding rate and increased Part D direct subsidy resulting from the IRA, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the company's progress on its previously discussed tactical cost cutting and transformation initiatives combined with the beneficial impact of prior value creation initiatives that have driven administrative cost efficiencies.

These factors were partially offset by the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• impact of the previously disclosed BY 2026 Star Ratings headwind, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• a higher CenterWell operating cost ratio.

*Refer to the "Footnotes" section included herein for a reconciliation of GAAP to Adjusted (non-GAAP) consolidated operating cost ratios for the respective periods.* 

**<u>Balance sheet</u>**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Days in claims payable (DCP) of 33.9 days at March 31, 2026 represented an increase of 2.0 days from 31.9 days at December 31, 2025 and a decrease of 4.9 days from 38.8 days at March 31, 2025.

The sequential increase was primarily driven by a higher total estimate of benefits payable for claims incurred but not reported (IBNR) as of March 31, 2026 driven by the 2026 membership growth. The total estimate of benefits payable for claims IBNR (included in the benefits payable line of the balance sheet) as of March 31, 2026 increased by approximately 35 percent compared to the balances at December 31, 2025. The benefits expense per day for 1Q26 grew by approximately 20 percent compared to the fourth quarter of 2025.

------

The year-over-year decrease was primarily impacted by an increased proportion of Medicare prescription drug benefit expense due to structural changes associated with the previous implementation of the IRA. Pharmacy claims are processed more quickly than medical claims leading to a lower benefits payable for claims IBNR and DCP. The decline was further impacted by lower reserve requirements in provider-capitation accruals, including the impact of payments to providers in accordance with the respective risk-sharing arrangements.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**•** Humana's debt-to-total capitalization at March 31, 2026 increased 190 basis points to 43.0 percent from 41.1 percent at December 31, 2025 reflective of the company's $1.0 billion public offering announced in March 2026, partially offset by the impact of the 1Q26 net earnings.

**<u>Operating cash flows</u>**

1Q26 GAAP operating cash flows increased from 1Q25 as a result of favorable working capital activity, primarily associated with an increase in the IBNR balance as previously discussed, modestly offset by a decline in net earnings in 1Q26.

**<u>Share repurchases</u>**

---

| | |
|:---|:---|
| | **1Q26** |
| **Total number of shares repurchased** | **564400** |
| **Average price paid per share** | **$182.13** |
| **Remaining repurchase authorization as of April 28, 2026** | **$2.72 billion** |

---

***<u>Humana's Insurance Segment</u>***

*This segment is comprised of insurance products serving Medicare and state-based contract beneficiaries, as well as individuals and employers. The segment also includes the company's Pharmacy Benefit Manager, or PBM, business.* 

---

| | | |
|:---|:---|:---|
| **Insurance Segment Results**<br> *($ in millions)* | **1Q26 (a)** | **1Q25 (a)** |
| Revenues | **$38059** | $30937 |
| Benefit ratio | **89.4%** | 87.4% |
| Operating cost ratio | **7.3%** | 8.2% |
| Income from operations | **$1435** | $1574 |
| Income from operations - Adjusted (non-GAAP) | **$1439** | $1578 |

---

*Refer to the "Footnotes" section included herein for further explanation of the disclosure for the Adjusted (non-GAAP) financial measure, as well as the reconciliation.*

**<u>Insurance Segment Revenues</u>**

The year-over-year increase in the GAAP segment revenues from 1Q25 primarily reflected the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• membership growth across the company's Medicare businesses in 2026, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• higher per member MA and stand-alone PDP premiums largely driven by an increase in MA benchmark funding from CMS and the increased Part D direct subsidy as a result of the IRA.

These factors were partially offset by the previously disclosed BY 2026 Star Ratings headwind.

**<u>Insurance Segment Benefit Ratio</u>**

The year-over-year increase in the GAAP segment benefit ratio primarily reflected the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the BY 2026 Star Ratings revenue headwind,

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the effect of the individual MA membership growth during the most recent AEP and OEP as the new members, on average, run at a higher benefit ratio as compared to retained members (excluding the impact of the BY 2026 Star Ratings headwind), and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the anticipated lower favorable prior period development in 1Q26.

These factors were partially offset by the following factors:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 2026 individual MA pricing, inclusive of the MA funding environment (excluding the BY 2026 Star Ratings headwind) combined with the company's ongoing clinical excellence efforts, more than offsetting the assumption of claims trend (with largely stable benefits year over year), and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the benefit of the company's group MA recontracting efforts for the 2026 plan year.

**<u>Insurance Segment Operating Cost Ratio</u>**

The significant year-over-year decrease in the GAAP segment operating cost ratio from 1Q25 primarily related to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• operating leverage associated with increased revenues from membership growth across the company's Medicare businesses in 2026 combined with an improved MA benchmark funding rate and the increased Part D direct subsidy resulting from the IRA, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the company's progress on its tactical cost cutting and transformation initiatives combined with the beneficial impact of prior value creation initiatives that have driven administrative cost efficiencies.

These factors were partially offset by the impact of the previously disclosed BY 2026 Star Ratings headwind.

***<u>Humana's CenterWell Segment</u>***

*This segment includes pharmacy solutions (excluding the PBM operations), primary care, and home solutions. Services offered by this segment are designed to enhance the overall healthcare experience. These services may lead to lower utilization associated with improved member health and/or lower drug costs.*

---

| | | |
|:---|:---|:---|
| **CenterWell Segment Results**<br> *($ in millions)* | **1Q26** | **1Q25** |
| Revenues | **$6100** | $5095 |
| Operating cost ratio | **94.5%** | 91.1% |
| Income from operations | **$289** | $392 |
| Income from operations - Adjusted (non-GAAP) (c) | **$338** | $451 |

---

*Refer to the "Footnotes" section included herein for further explanation of the disclosure for the Adjusted (non-GAAP) financial measure, as well as the reconciliation.*

**<u>CenterWell Segment Revenues</u>**

The favorable year-over-year CenterWell GAAP segment revenues comparison was primarily driven by the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• higher revenues associated with growth in each of the CenterWell business lines resulting from increased Medicare membership in 2026, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• continued expansion of the company's payor-agnostic client base, primarily associated with the company's primary care business as a result of recent acquisitions.

------

These factors were partially offset by the impact of the final year of the phase-in of the v28 risk model revision.

**<u>CenterWell Segment Operating Cost Ratio</u>**

The year-over-year increase in the segment's GAAP operating cost ratio primarily resulted from the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• final year of the phase-in of the v28 risk model revision, along with certain year-over-year timing impacts,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the uptick of volume within CenterWell Specialty Pharmacy, which carries a higher operating cost ratio than the traditional pharmacy business,

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the anticipated headwind in 1Q26 associated with the previously disclosed acquisition of The Villages Health, which closed in November 2025, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• transaction and integration costs associated with the recently disclosed acquisition of MaxHealth in 1Q26.

These factors were partially offset by the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• continued maturation of the v28 mitigation activities within the primary care business, and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• the company's progress on its tactical cost cutting and transformation initiatives combined with the beneficial impact of prior value creation initiatives that have driven administrative cost efficiencies.

See additional operational metrics for the CenterWell segment on pages S-11 and S-12 of the statistical supplement included in this earnings release.

***<u>Conference Call</u>***

Humana will host a live question-and-answer session for analysts at 8:00 a.m. Eastern time today to discuss its financial results for the quarter and the company's expectations for future earnings. In advance of the question-and-answer session, Humana will post prepared management remarks to the Quarterly Results section of its Investor Relations page (https://humana.gcs-web.com/financial-information/quarterly-results).

A webcast of the 1Q26 earnings call may be accessed via Humana's Investor Relations page at https://humana.gcs-web.com/.

If you anticipate asking a question during the question-and-answer session, please register in advance at this link - https://register-conf.media-server.com/register/BId1413c4c078343e28841e18c372f7b58.

Upon registration, telephone participants will receive a confirmation email detailing how to join the conference call, including the dial-in number and a unique registrant ID.

The company suggests participants listening via the web or the conference call sign in or dial in at least 15 minutes in advance of the call. For those unable to participate in the live event, the virtual presentation archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page at https://humana.gcs-web.com/, approximately two hours following the live webcast.

***<u>Footnotes</u>***

The company has included financial measures throughout this earnings release that are not in accordance with GAAP. Management believes that these measures, when presented in conjunction with the corresponding GAAP measures, provide a comprehensive perspective to more accurately compare and analyze the company's core operating performance over time. Consequently, management uses these non-GAAP (Adjusted) financial measures as consistent indicators of the company's core business operations from period to period, as well as for planning and decision-making purposes and in determination of incentive compensation. Non-GAAP (Adjusted) financial measures should be considered in addition to, but not as a substitute for, or superior to, financial measures prepared in accordance with GAAP. The company's non-GAAP measures are not intended to normalize earnings, eliminate volatility, or represent

------

future performance. Non-GAAP measures are subject to inherent limitations and may differ from similarly titled measures used by other companies. All financial measures in this earnings release are in accordance with GAAP unless otherwise indicated. Please refer to the footnotes for a detailed description of each item adjusted out of GAAP financial measures to arrive at non-GAAP (Adjusted) financial measures.

(a) For the periods covered in this earnings release, the following items are excluded from the non-GAAP financial measures described above, as applicable.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Amortization associated with identifiable intangibles -** Since amortization varies based on the size and timing of acquisition activity, management believes the exclusion of this non-cash expense provides a more consistent and uniform indicator of performance from period to period. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results, EPS, and Insurance and CenterWell segments' income from operations. The table below discloses respective period amortization expense for each segment:

---

| | | |
|:---|:---|:---|
| **Amortization** <br>*(in millions)* | **1Q26** | **1Q25** |
| Insurance segment | **$4** | $4 |
| CenterWell segment | **$7** | $11 |

---

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Put/call valuation adjustments associated with the company's non-consolidating minority interest investments -** These non-cash amounts are the result of fair value measurements associated with the company's primary care strategic partnership and are unrelated to the company's core business performance. For all periods shown within this earnings release, GAAP measures affected include consolidated pretax results and EPS.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Value creation initiatives -** These charges relate to the company's multi-year transformation program, as approved by management with defined scope and milestones. The intent of the program is to re-align the company's cost structure, operating model, and technology footprint with evolving market conditions. These costs primarily include severance and associate exit costs, asset impairments, and external consulting expenses incurred to execute the program. These charges were recorded at the corporate level and not allocated to the segments. The company has consistently applied this adjustment across all periods. For all periods shown within this earnings release, GAAP measures affected in this release include consolidated pretax results, EPS, and the consolidated operating cost ratio.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**• Cumulative net tax impact -** This adjustment represents the cumulative net impact of the corresponding tax benefit or expense at the applicable marginal rate related to the aforementioned items excluded from the applicable GAAP measures. For FY 2025, the tax adjustment reflects the impact of the loss on sale of business, which exceeded the book loss. The related tax benefit from the loss on sale of business is realizable via capital loss carryback. The tax impact of the aforementioned items differs from the statutory rates due to jurisdictional mix, limitations on deductibility, and other factors. The cumulative tax impact is not intended to represent a normalized effective tax rate or expected future tax outcomes. For all periods presented in this earnings release, EPS is the sole GAAP measure affected.

The following adjustments impact only the FY 2025 GAAP EPS shown within this release on page 2.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;***•* Impact of exit of employer group commercial medical products business -** These amounts relate to activity from the exit of the employer group commercial medical products business as announced by Humana on February 23, 2023.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Settlement of certain litigation expenses -** These charges relate to expenses the company recognized in connection with a discrete legal matter. The nature and magnitude of this settlement are not indicative of the company's ongoing operations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Loss on sale of business -** This discrete disposition is not part of the company's ordinary course operations and the impacts recognized from the disposal do not reflect core operational performance. The loss primarily reflects the difference between the carrying value and proceeds at the time of sale.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• **Impairment charges -** The company recognized non-cash impairment charges related to certain indefinite-lived intangible assets based on the company's estimate of future financial performance in certain state markets. Additionally, the company recognized non-cash impairment charges in the fourth quarter of 2025 related to a discrete joint-venture investment for which the company held minority ownership interests that were deemed to be unrecoverable based on recent market activity. These charges were recorded at the corporate level and not allocated to the segments.

In addition to the reconciliations shown on page 2 of this release, the following are reconciliations of GAAP to Adjusted (non-GAAP) measures described above and disclosed within this earnings release:

------

***<u>Operating cost ratio</u>***

---

| | | |
|:---|:---|:---|
| **CONSOLIDATED<br>Operating cost ratio** | **1Q26** | **1Q25** |
| **GAAP** | **10.2%** | 10.6% |
| Value creation initiatives | **(0.2)%** | (0.1)% |
| **Adjusted (non-GAAP)** | **10.0%** | 10.5% |

---

***<u>Insurance Segment - Income from operations</u>***

---

| | | |
|:---|:---|:---|
| **INSURANCE SEGMENT**<br>**Income from operations** <br>*(in millions)* | **1Q26** | **1Q25** |
| **GAAP** | **$1435** | $1574 |
| Amortization associated with identifiable intangibles | **4** | 4 |
| **Adjusted (non-GAAP)** | **$1439** | $1578 |

---

(b) FY 2026 GAAP EPS guidance and FY 2026 Adjusted (non-GAAP) EPS guidance exclude the impact of future value changes to items that have not yet been recognized and cannot currently be reasonably estimated at this time.

(c) The CenterWell segment non-GAAP (Adjusted) income from operations includes an adjustment to add back depreciation and amortization expense to the segment's GAAP income from operations since such an adjustment is commonly utilized for valuation purposes within the healthcare delivery industry.

---

| | | |
|:---|:---|:---|
| **CENTERWELL SEGMENT** <br>**Income from operations** <br>*(in millions)* | **1Q26** | **1Q25** |
| **GAAP** | **$289** | $392 |
| Depreciation and amortization expense | **49** | 59 |
| **Adjusted (non-GAAP)** | **$338** | $451 |

---

**<u>Cautionary Statement</u>**

This news release includes forward-looking statements regarding Humana within the meaning of the Private Securities Litigation Reform Act of 1995. When used in investor presentations, press releases, Securities and Exchange Commission (SEC) filings, and in oral statements made by or with the approval of one of Humana's executive officers, the words or phrases like "expects," "believes," "anticipates," "assumes," "intends," "likely will result," "estimates," "projects" or variations of such words and similar expressions are intended to identify such forward-looking statements.

These forward-looking statements are not guarantees of future performance and are subject to risks, uncertainties, and assumptions, including, among other things, information set forth in the "Risk Factors" section of the company's SEC filings, a summary of which includes but is not limited to the following:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If Humana does not design and price its products properly and competitively, if the premiums Humana receives are insufficient to cover the cost of healthcare services delivered to its members, if the company is unable to implement clinical initiatives to provide a better healthcare experience for its members, lower costs and appropriately document the risk profile of its members, or if its estimates of benefits expense are inadequate, Humana's profitability could be materially adversely affected. Humana estimates the costs of its benefit expense payments, and designs and prices its products accordingly, using actuarial methods and assumptions based upon, among other relevant factors, claim payment patterns, medical cost inflation, and historical developments such as claim inventory levels and claim receipt patterns. The company continually reviews estimates of future payments relating to benefit expenses for services incurred in the current and prior periods and makes necessary adjustments to its reserves, including premium deficiency reserves,

------

where appropriate. These estimates involve extensive judgment, and have considerable inherent variability because they are extremely sensitive to changes in claim payment patterns and medical cost trends. Accordingly, Humana's reserves may be insufficient.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If Humana fails to effectively implement its operational and strategic initiatives, including its Medicare initiatives, which are of particular importance given the concentration of the company's revenues in these products, state-based contract strategy, the growth of its CenterWell business, and its integrated care delivery model, the company's business may be materially adversely affected.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• The number of Humana's Medicare Advantage plans rated 4-star or higher significantly declined in 2025. Humana filed a lawsuit seeking to set aside and vacate the 2025 Star Ratings of its Medicare Advantage plans, and on October 14, 2025, the Court issued a decision rejecting Humana's challenge. Although the company has appealed that decision, there can be no assurances that it will ultimately prevail in the lawsuit. If the company is not successful, the decline in Star Ratings will negatively impact its 2026 quality bonus payments from CMS and may also significantly adversely affect the company's revenues, operating results, and cash flows. In addition, there can be no assurances the company will be successful in maintaining or improving its Star Ratings in future years.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Humana is involved in various legal actions, or disputes that could lead to legal actions (such as, among other things, provider contract disputes and qui tam litigation brought by individuals on behalf of the government), governmental and internal investigations, and routine internal review of business processes any of which, if resolved unfavorably to the company, could result in substantial monetary damages or changes in its business practices. Increased litigation and negative publicity could also increase the company's cost of doing business.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• As a government contractor, Humana is exposed to risks that may materially adversely affect its business or its willingness or ability to participate in government healthcare programs including, among other things, loss of material government contracts; governmental audits and investigations; potential inadequacy of government determined payment rates; potential restrictions on profitability, including by comparison of profitability of the company's Medicare Advantage business to non-Medicare Advantage business; or other changes in the governmental programs in which Humana participates. Changes to the risk-adjustment model utilized by CMS to adjust premiums paid to Medicare Advantage plans or retrospective recovery by CMS of previously paid premiums as a result of the final rule related to the risk adjustment data validation audit methodology published by CMS on January 30, 2023 (Final RADV Rule), which Humana believes fails to address adequately the statutory requirement of actuarial equivalence and violates the Administrative Procedure Act due to its failure to include a "Fee for Service Adjuster" could have a material adverse effect on the company's operating results, financial position and cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Humana's business activities are subject to substantial government regulation. New laws or regulations, or legislative, judicial, or regulatory changes in existing laws or regulations or their manner of application could increase the company's cost of doing business and have a material adverse effect on Humana's results of operations (including restricting revenue, enrollment and premium growth in certain products and market segments, restricting the company's ability to expand into new markets, increasing the company's medical and operating costs by, among other things, requiring a minimum benefit ratio on insured products, lowering the company's Medicare payment rates and increasing the company's expenses associated with a non-deductible health insurance industry fee and other assessments); the company's financial position (including the company's ability to maintain the value of its goodwill); and the company's cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Humana's failure to manage acquisitions, divestitures and other significant transactions successfully may have a material adverse effect on the company's results of operations, financial position, and cash flows.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• If Humana fails to develop and maintain satisfactory relationships with the providers of care to its members, the company's business may be adversely affected.

------

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Humana faces significant competition in attracting and retaining talented employees. Further, managing succession for, and retention of, key executives is critical to the Company's success, and its failure to do so could adversely affect the Company's businesses, operating results and/or future performance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Humana's pharmacy business is highly competitive and subjects it to regulations and supply chain risks in addition to those the company faces with its core health benefits businesses.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Changes in the prescription drug industry pricing benchmarks may adversely affect Humana's financial performance.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Humana's ability to obtain funds from certain of its licensed subsidiaries is restricted by state insurance regulations.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Downgrades in Humana's debt ratings, should they occur, may adversely affect its business, results of operations, and financial condition.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Volatility or disruption in the securities and credit markets may significantly and adversely affect the value of our investment portfolio and the investment income that we derive from this portfolio.

In making forward-looking statements, Humana is not undertaking to address or update them in future filings or communications regarding its business or results. In light of these risks, uncertainties, and assumptions, the forward-looking events discussed herein may or may not occur. There also may be other risks that the company is unable to predict at this time. Any of these risks and uncertainties may cause actual results to differ materially from the results discussed in the forward-looking statements.

Humana advises investors to read the following documents as filed by the company with the SEC for further discussion both of the risks it faces and its historical performance:

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Form 10-K for the year ended December 31, 2025; and

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Form 8-Ks filed during 2026.

***<u>About Humana</u>***

Humana (NYSE: HUM) is a leading U.S. healthcare company. Through our Humana insurance services and our CenterWell health care services, we make it easier for the millions of people we serve to achieve their best health – delivering the care and service they need, when they need it. These efforts are leading to a better quality of life for people with Medicare and Medicaid, families, individuals, military service personnel, and communities at large. Learn more about what we offer at Humana.com and at CenterWell.com.

------

---

| | | |
|:---|:---|:---|
| **<u>Humana Inc. FY 2026 Guidance - As of April 29, 2026</u>** | **<u>Humana Inc. FY 2026 Guidance - As of April 29, 2026</u>** | **<u>Humana Inc. FY 2026 Guidance - As of April 29, 2026</u>** |
| ***no changes from initial FY 2026 guidance provided as of February 11, 2026, with the exception of GAAP EPS*** | ***no changes from initial FY 2026 guidance provided as of February 11, 2026, with the exception of GAAP EPS*** | ***no changes from initial FY 2026 guidance provided as of February 11, 2026, with the exception of GAAP EPS*** |
| **<u>Diluted earnings per common share (EPS)</u>** | **<u>Diluted earnings per common share (EPS)</u>** | **<u>Diluted earnings per common share (EPS)</u>** |
| | **GAAP:** 'at least $8.36'<br>(previously 'at least $8.89') | |
| | **Non-GAAP:** 'at least $9.00' | |
| **<u>Total Revenues</u>** | **<u>Total Revenues</u>** | **<u>Total Revenues</u>** |
| Consolidated | At least $160 billion | Consolidated and segment level revenue projections include expected investment income.<br>Segment level revenues include amounts that eliminate in consolidation. |
| Insurance segment | At least $155 billion | Consolidated and segment level revenue projections include expected investment income.<br>Segment level revenues include amounts that eliminate in consolidation. |
| CenterWell segment | At least $25 billion | Consolidated and segment level revenue projections include expected investment income.<br>Segment level revenues include amounts that eliminate in consolidation. |
| **<u>Change in year-end medical membership from prior year-end</u>** | **<u>Change in year-end medical membership from prior year-end</u>** | **<u>Change in year-end medical membership from prior year-end</u>** |
| Individual Medicare Advantage | growth of approximately 25 percent |  |
| Group Medicare Advantage | growth of approximately 150,000 |  |
| Individual Medicare stand-alone PDP | growth of approximately 1,000,000 |  |
| State-based contracts | growth of 25,000 to 100,000 | State-based contracts guidance includes membership in Florida, Illinois, Indiana, Kentucky, Louisiana, Michigan, Ohio, Oklahoma, South Carolina, Virginia, and Wisconsin. |
| **Benefit Ratio** Insurance segment | **GAAP:** 92.75% +/- 25 bps | Ratio calculation: benefits expense as a percent of premiums revenues. |
| **Operating Cost Ratio** Consolidated | **GAAP:** 10.0% +/- 25 bps | Ratio calculation: operating costs excluding depreciation and amortization as a percent of revenues excluding investment income. |
| **<u>Segment Results</u>** | **<u>Segment Results</u>** | **<u>Segment Results</u>** |
| Insurance segment income from operations | **GAAP:** approximately breakeven |  |
| CenterWell segment income from operations | **GAAP:** $1.3B to $1.8B<br>**Non-GAAP:** $1.5B to $2.0B | CenterWell segment Non-GAAP income from operations excludes the projected impact of segment depreciation and amortization. |
| **Effective Tax Rate** | **GAAP:** approximately 25.5% |  |
| **Weighted Avg. Share Count for Diluted EPS** | approximately 121 million |  |
| **Cash flows from operations** | **GAAP:** $2.5 billion to $2.9 billion |  |
| **Capital expenditures** | approximately $650 million |  |

---

------

Humana Inc.

Statistical Schedules

and

Supplementary Information

1Q26 Earnings Release

------

---

| | |
|:---|:---|
| **Humana Inc.<br>Statistical Schedules and Supplementary Information <br>1Q26 Earnings Release** | **Humana Inc.<br>Statistical Schedules and Supplementary Information <br>1Q26 Earnings Release** |
| (S-3) | Summary of Results - Consolidated and Segments - Quarter |
| (S-4) | Consolidated Statements of Income - Quarter |
| (S-5) | Consolidated Balance Sheets |
| (S-6) | Consolidated Statements of Cash Flows - Year to Date |
| (S-7) - (S-8) | Consolidating Statements of Income - Quarter |
| (S-9) | Membership Detail |
| (S-10) | Premiums and Services Revenue Detail |
| (S-11) - (S-12) | CenterWell Segment - Pharmacy & Home Solutions and Primary Care |
| (S-13) | Footnotes |

---

------

---

| | | |
|:---|:---|:---|
| **Humana Inc. Summary of Results**<br> *($ in millions, except per share amounts)* | **1Q26 (a)** | **1Q25 (a)** |
| **CONSOLIDATED** | **CONSOLIDATED** | **CONSOLIDATED** |
| Revenues | **$39648** | $32112 |
| Pretax results | **$1595** | $1691 |
| Pretax results - Adjusted (non-GAAP) | **$1670** | $1893 |
| EPS | **$9.83** | $10.30 |
| EPS - Adjusted (non-GAAP) | **$10.31** | $11.58 |
| Benefit ratio | **89.4%** | 87.0% |
| Operating cost ratio | **10.2%** | 10.6% |
| Operating cost ratio - Adjusted (non-GAAP) | **10.0%** | 10.5% |
| Operating cash flows | **$1254** | $331 |
| Parent company cash and short-term investments | **$111** | $1234 |
| Debt-to-total capitalization | **43.0%** | 42.8% |
| Days in Claims Payable (DCP) | **33.9** | 38.8 |
| **INSURANCE SEGMENT** | **INSURANCE SEGMENT** | **INSURANCE SEGMENT** |
| Revenues | **$38059** | $30937 |
| Benefit ratio | **89.4%** | 87.4% |
| Operating cost ratio | **7.3%** | 8.2% |
| Income from operations | **$1435** | $1574 |
| Income from operations - Adjusted (non-GAAP) | **$1439** | $1578 |
| **CENTERWELL SEGMENT** | **CENTERWELL SEGMENT** | **CENTERWELL SEGMENT** |
| Revenues | **$6100** | $5095 |
| Operating cost ratio | **94.5%** | 91.1% |
| Income from operations | **$289** | $392 |
| Income from operations - Adjusted (non-GAAP) (c) | **$338** | $451 |

---

*Refer to the "Footnotes" section included in the previous narrative portion of this release (beginning on page 7) for further explanation of disclosures for* 

*Adjusted (non-GAAP) financial measures, as well as reconciliations.*

------

Humana Inc.

Consolidated Statements of Income (Unaudited)

*Dollars in millions, except per common share results*

---

| | | |
|:---|:---|:---|
| | **For the three months ended <br>March 31,** | **For the three months ended <br>March 31,** |
| | **2026** | 2025 |
| Revenues: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Premiums | $**37709** | $30514 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Services | **1677** | 1334 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment income | **262** | 264 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total revenues** | **39648** | 32112 |
| Operating expenses: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Benefits | **33707** | 26535 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Operating costs | **4024** | 3380 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Depreciation and amortization | **163** | 183 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total operating expenses** | **37894** | 30098 |
| **Income from operations** | **1754** | 2014 |
| Interest expense | **193** | 160 |
| Other (income) expense, net | **(34)** | 163 |
| **Income before income taxes and equity in net losses** | **1595** | 1691 |
| Provision from income taxes | **395** | 406 |
| Equity in net losses (A) | **(16)** | (43) |
| **Net income** | **1184** | 1242 |
| Net loss attributable to noncontrolling interests | **2** | 2 |
| **Net income attributable to Humana** | $**1186** | $1244 |
| Basic earnings per common share | $**9.85** | $10.31 |
| **Diluted earnings per common share** | $**9.83** | $10.30 |
| Shares used in computing basic earnings per common share (000's) | **120332** | 120666 |
| Shares used in computing diluted earnings per common share (000's) | **120652** | 120844 |

---

------

Humana Inc.

Consolidated Balance Sheets (Unaudited)

*Dollars in millions, except share amounts*

---

| | | |
|:---|:---|:---|
| | **March 31,**<br>**2026** | December 31,<br>2025 |
| **<u>Assets</u>** |  |  |
| Current assets: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Cash and cash equivalents | $**4951** | $4200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Investment securities | **17014** | 15703 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Receivables, net | **5218** | 3270 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Other current assets | **10897** | 9560 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current assets | **38080** | 32733 |
| Property and equipment, net | **2170** | 2231 |
| Long-term investment securities | **626** | 493 |
| Equity method investments | **633** | 638 |
| Goodwill | **10489** | 9686 |
| Other long-term assets | **3282** | 3128 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total assets** | $**55280** | $48909 |
| **<u>Liabilities and Stockholders' Equity</u>** |  |  |
| Current liabilities: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Benefits payable | $**12691** | $9967 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Trade accounts payable and accrued expenses | **6531** | 5717 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Book overdraft | **297** | 306 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Unearned revenues | **269** | 356 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Short-term debt | **1719** |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Total current liabilities | **21507** | 16346 |
| Long-term debt | **12274** | 12369 |
| Other long-term liabilities | **2853** | 2457 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities** | **36634** | 31172 |
| Commitments and contingencies |  |  |
| Stockholders' equity: |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Preferred stock, $1 par; 10,000,000 shares authorized, none issued | **—** |  |
| Common stock, $0.16 2/3 par; 300,000,000 shares authorized; 198,719,832 issued at March 31, 2026 | **33** | 33 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Capital in excess of par value | **3641** | 3600 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Retained earnings | **30153** | 29075 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Accumulated other comprehensive loss | **(731)** | (633) |
| Treasury stock, at cost, 78,658,332 shares at March 31, 2026 | **(14516)** | (14418) |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total stockholders' equity** | **18580** | 17657 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Noncontrolling interests | **66** | 80 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total equity** | **18646** | 17737 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total liabilities and equity** | $**55280** | $48909 |
| **Debt-to-total capitalization ratio** | **43.0%** | 41.1% |

---

------

Humana Inc.

Consolidated Statements of Cash Flows (Unaudited) *Dollars in millions* 

---

| | | |
|:---|:---|:---|
| | **For the three months ended March 31,** | **For the three months ended March 31,** |
| | **2026** | **2025** |
| **Cash flows from operating activities** |  |  |
| Net income | $**1184** | $1242 |
| Adjustments to reconcile net income to net cash provided by operating activities: |  |  |
| Loss (gain) on investment securities, net | **1** | (2) |
| Equity in net losses | **16** | 43 |
| Stock-based compensation | **51** | 49 |
| Depreciation | **183** | 200 |
| Amortization | **11** | 15 |
| Impairment of property and equipment | **2** | 9 |
| Changes in operating assets and liabilities, net of effect of businesses acquired and disposed: |  |  |
| Receivables | **(1914)** | (1755) |
| Other assets | **(1390)** | (686) |
| Benefits payable | **2724** | 1011 |
| Other liabilities | **452** | 193 |
| Unearned revenues | **(87)** | 5 |
| Other, net | **21** | 7 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by operating activities** | **1254** | 331 |
| **Cash flows from investing activities** |  |  |
| Acquisitions, net of cash acquired | **(911)** |  |
| Purchases of property and equipment, net | **(121)** | (95) |
| Changes in securities lending collateral receivable | **55** | (175) |
| Purchases of investment securities | **(2894)** | (827) |
| Proceeds from maturities of investment securities | **923** | 889 |
| Proceeds from sales of investment securities | **395** | 522 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net cash (used in) provided by investing activities** | **(2553)** | 314 |
| **Cash flows from financing activities** |  |  |
| Receipts (payments) from contract deposits, net | **673** | (35) |
| Proceeds from issuance of notes, net | **990** | 1481 |
| Repayments of notes | **(10)** |  |
| Proceeds (repayments) from issuance of commercial paper, net | **693** | (4) |
| Debt issue costs | **—** | (3) |
| Change in book overdraft | **(9)** | (33) |
| Common stock repurchases | **(107)** | (9) |
| Dividends paid | **(107)** | (108) |
| Change in securities lending payable | **(55)** | 175 |
| Change in rebate factor payable | **—** | (68) |
| Other | **(18)** | (12) |
| &nbsp;&nbsp;&nbsp;&nbsp;**Net cash provided by financing activities** | **2050** | 1384 |
| Increase in cash and cash equivalents | **751** | 2029 |
| Cash and cash equivalents at beginning of period | **4200** | 2221 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Cash and cash equivalents at end of period** | $**4951** | $4250 |

---

------

Humana Inc.

Consolidating Statements of Income—For the three months ended March 31, 2026 (Unaudited)

*In millions* 

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Insurance** | **CenterWell** | **Eliminations/<br>Corporate** | **Consolidated** |
| **Revenues—external customers Premiums:** | | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;Individual Medicare Advantage | $28252 | $— | $— | $28252 |
| &nbsp;&nbsp;&nbsp;&nbsp;Group Medicare Advantage | 2911 |  |  | 2911 |
| &nbsp;&nbsp;&nbsp;&nbsp;Medicare stand-alone PDP | 2617 |  |  | 2617 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Medicare** | 33780 |  |  | 33780 |
| &nbsp;&nbsp;&nbsp;&nbsp;State-based contracts and other | 3332 |  |  | 3332 |
| &nbsp;&nbsp;&nbsp;&nbsp;Specialty benefits | 268 |  |  | 268 |
| &nbsp;&nbsp;&nbsp; Medicare Supplement | 329 |  |  | 329 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total premiums** | 37709 |  |  | 37709 |
| &nbsp;&nbsp;&nbsp;**Services revenue:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;Home solutions |  | 343 |  | 343 |
| &nbsp;&nbsp;&nbsp;&nbsp;Primary care |  | 788 |  | 788 |
| &nbsp;&nbsp;&nbsp;&nbsp;Pharmacy solutions |  | 297 |  | 297 |
| &nbsp;&nbsp;&nbsp;&nbsp;Military services and other | 247 |  | 2 | 249 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total services revenue** | 247 | 1428 | 2 | 1677 |
| **Total revenues—external customers** | 37956 | 1428 | 2 | 39386 |
| Intersegment revenues | 1 | 4672 | (4673) |  |
| Investment income | 102 |  | 160 | 262 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total revenues** | 38059 | 6100 | (4511) | 39648 |
| **Operating expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Benefits | 33698 |  | 9 | 33707 |
| &nbsp;&nbsp;&nbsp;Operating costs | 2784 | 5762 | (4522) | 4024 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 142 | 49 | (28) | 163 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total operating expenses** | 36624 | 5811 | (4541) | 37894 |
| **Income from operations** | $1435 | $289 | $30 | $1754 |
| **Benefit ratio** | 89.4% |  |  | 89.4% |
| **Operating cost ratio** | 7.3% | 94.5% |  | 10.2% |

---

------

Humana Inc.

Consolidating Statements of Income—For the three months ended March 31, 2025 (Unaudited)

*In millions*

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **Insurance** | **CenterWell** | **Eliminations/<br>Corporate** | **Consolidated** |
| **Revenues—external customers Premiums:** | | | | |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Individual Medicare Advantage | $22681 | $— | $— | $22681 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Group Medicare Advantage | 2322 |  |  | 2322 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medicare stand-alone PDP | 1448 |  |  | 1448 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Medicare** | 26451 |  |  | 26451 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;State-based contracts and other | 3568 |  |  | 3568 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specialty benefits | 244 |  |  | 244 |
| &nbsp;&nbsp;&nbsp;&nbsp;Medicare Supplement | 251 |  |  | 251 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total premiums** | 30514 |  |  | 30514 |
| &nbsp;&nbsp;&nbsp;**Services revenue:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Home solutions |  | 335 |  | 335 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Primary care |  | 469 |  | 469 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharmacy solutions |  | 278 |  | 278 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Military services and other | 252 |  |  | 252 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total services revenue** | 252 | 1082 |  | 1334 |
| **Total revenues—external customers** | 30766 | 1082 |  | 31848 |
| Intersegment revenues | 1 | 4013 | (4014) |  |
| Investment income | 170 |  | 94 | 264 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total revenues** | 30937 | 5095 | (3920) | 32112 |
| **Operating expenses:** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;Benefits | 26675 |  | (140) | 26535 |
| &nbsp;&nbsp;&nbsp;Operating costs | 2534 | 4644 | (3798) | 3380 |
| &nbsp;&nbsp;&nbsp;Depreciation and amortization | 154 | 59 | (30) | 183 |
| &nbsp;&nbsp;&nbsp;&nbsp;**Total operating expenses** | 29363 | 4703 | (3968) | 30098 |
| **Income from operations** | $1574 | $392 | $48 | $2014 |
| **Benefit ratio** | 87.4% |  |  | 87.0% |
| **Operating cost ratio** | 8.2% | 91.1% |  | 10.6% |

---

------

Humana Inc.

Membership Detail (Unaudited)

*In thousands*

---

| | | | | |
|:---|:---|:---|:---|:---|
| *Members may not be unique to each product since members have the ability to enroll in more than one product.* | *Members may not be unique to each product since members have the ability to enroll in more than one product.* | *Members may not be unique to each product since members have the ability to enroll in more than one product.* | *Members may not be unique to each product since members have the ability to enroll in more than one product.* | *Members may not be unique to each product since members have the ability to enroll in more than one product.* |
|  | **March 31, 2026** | **Average 1Q26** | March 31, 2025 | December 31, 2025 |
| **Medical Membership:** |  |  |  |  |
| Individual Medicare Advantage\* | **6393.3** | **6347.4** | 5215.8 | 5249.3 |
| Group Medicare Advantage (B) | **729.2** | **729.8** | 572.6 | 568.4 |
| Total Medicare Advantage | **7122.5** | **7077.2** | 5788.4 | 5817.7 |
| Medicare stand-alone PDP (B) | **3860.6** | **3857.3** | 2433.1 | 2462.6 |
| Total Medicare | **10983.1** | **10934.5** | 8221.5 | 8280.3 |
| Medicare Supplement | **536.8** | **531.5** | 420.5 | 498.4 |
| State-based contracts and other (C) | **1561.3** | **1573.7** | 1608.1 | 1615.6 |
| Military services | **4630.2** | **4630.2** | 4588.9 | 4605.4 |
| **Total Medical Membership** | **17711.4** | **17669.9** | 14839.0 | 14999.7 |
| **Specialty Membership:** |  |  |  |  |
| Dental—fully-insured (D) | **2206.5** | **2207.4** | 2095.9 | 2107.6 |
| Dental—ASO | **317.7** | **319.3** | 312.8 | 307.5 |
| Total Dental | **2524.2** | **2526.7** | 2408.7 | 2415.1 |
| Vision | **1971.6** | **1977.1** | 1906.0 | 1926.2 |
| Other supplemental benefits | **416.5** | **415.3** | 373.7 | 401.3 |
| **Total Specialty Membership** | **4912.3** | **4919.1** | 4688.4 | 4742.6 |
|  | **March 31, 2026** | **Member Mix<br>March 31, 2026** | March 31, 2025 | Member Mix<br>March 31, 2025 |
| **<u>Individual Medicare Advantage Membership</u>** |  |  |  |  |
| HMO | **3172.1** | **50%** | 2658.4 | 51% |
| PPO/PFFS | **3221.2** | **50%** | 2557.4 | 49% |
| **Total Individual Medicare Advantage**  | **6393.3** | **100%** | 5215.8 | 100% |
| **<u>Individual Medicare Advantage Membership</u>** |  |  |  |  |
| Shared Risk (E) | **2115.5** | **33%** | 1930.6 | 37% |
| Path to Risk (F) | **1973.3** | **31%** | 1571.1 | 30% |
| Total Value-based | **4088.8** | **64%** | 3501.7 | 67% |
| Other | **2304.5** | **36%** | 1714.1 | 33% |
| **Total Individual Medicare Advantage** | **6393.3** | **100%** | 5215.8 | 100% |

---

\*Individual Medicare Advantage membership includes 945,100 Dual Eligible Special Need Plan (D-SNP) members as of March 31, 2026, a net increase of 146,000, or 18 percent, from 799,100 as of March 31, 2025, and up 184,600, or 24 percent, from 760,500 as of December 31, 2025.

------

Humana Inc.

Premiums and Services Revenue Detail (Unaudited)

*Dollars in millions, except per member per month; includes intersegment revenues* 

---

| | | | | |
|:---|:---|:---|:---|:---|
| | **For the three months ended <br>March 31,** | **For the three months ended <br>March 31,** | **Per Member per Month (J)<br>For the three months ended March 31,** | **Per Member per Month (J)<br>For the three months ended March 31,** |
| | **2026** | 2025 | **2026** | 2025 |
| &nbsp;&nbsp;&nbsp;**Insurance** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Individual Medicare Advantage | $**28252** | $22681 | $**1484** | $1446 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Group Medicare Advantage | **2911** | 2322 | **1330** | 1347 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medicare stand-alone PDP | **2617** | 1448 | **226** | 200 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;State-based contracts and other (G) | **3332** | 3568 | **697** | 709 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Specialty benefits (H) | **268** | 244 | **19** | 19 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Medicare Supplement | **329** | 251 | **206** | 202 |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Military and other (I) | **248** | 253 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total** | **37957** | 30767 |  |  |
| &nbsp;&nbsp;&nbsp;**CenterWell** |  |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Pharmacy solutions | **3152** | 2844 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Primary care | **1922** | 1419 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;Home solutions | **1026** | 832 |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total** | **6100** | 5095 |  |  |

---

------

Humana Inc.

CenterWell Segment - Pharmacy & Home Solutions (Unaudited)

***<u>Pharmacy Solutions</u>***

---

| | | | |
|:---|:---|:---|:---|
| | **For the three months ended<br>March 31, 2026** | For the three months ended<br>March 31, 2025 | For the three months ended<br>December 31, 2025 |
| &nbsp;&nbsp;&nbsp;**<u>Generic Dispense Rate</u>** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Medicare** | **91.0%** | 91.0% | 90.1% |
| &nbsp;&nbsp;&nbsp;**<u>Mail-Order Penetration</u>** |  |  |  |
| &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;**Total Medicare** | **23.8%** | 26.0% | 25.7% |

---

***<u>Home Solutions</u>***

---

| | | | |
|:---|:---|:---|:---|
| | **For the three months ended<br>March 31, 2026** | **For the three months ended<br>March 31, 2025** | **Year-over-Year Growth** |
| **Episodic Admissions (K)** | 85650 | 82146 | 4.3% |
| **Total Admissions - Same Store (L)** | 114507 | 110569 | 3.6% |

---

------

Humana Inc.

CenterWell Segment - Primary Care (M) (Unaudited)

---

| | | | | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|:---|:---|:---|
| | **As of March 31, 2026 (1)** | **As of March 31, 2026 (1)** | **As of March 31, 2026 (1)** | **As of March 31, 2025** | **As of March 31, 2025** | **As of March 31, 2025** | **Year-over-Year Change** | **Year-over-Year Change** | **Year-over-Year Change** |
| |<br>**Center**<br>**Count** | **Primary**<br>**Care**<br>**Providers** |<br>**Patients**<br>**Served (N)** |<br>**Center**<br>**Count** | **Primary**<br>**Care**<br>**Providers** |<br>**Patients**<br>**Served (N)** |<br>**Center**<br>**Count** | **Primary**<br>**Care**<br>**Providers** |<br>**Patients**<br>**Served** |
| **De novo** | 146 | 465 | 130500 | 136 | 345 | 92000 | 7.4% | 34.8% | 41.8% |
| **Wholly-owned** | 252 | 1037 | 366300 | 193 | 759 | 254200 | 30.6% | 36.6% | 44.1% |
| **Independent Physician Associations** |  |  | 104800 |  |  | 71600 |  |  | 46.4% |
| **Total** | 398 | 1502 | 601600 | 329 | 1104 | 417800 | 21.0% | 36.1% | 44.0% |

---

---

| | | | | | | |
|:---|:---|:---|:---|:---|:---|:---|
| | **As of December 31, 2025 (2)** | **As of December 31, 2025 (2)** | **As of December 31, 2025 (2)** | **Sequential Change** | **Sequential Change** | **Sequential Change** |
| |<br>**Center**<br>**Count** | **Primary**<br>**Care**<br>**Providers** |<br>**Patients**<br>**Served (N)** |<br>**Center**<br>**Count** | **Primary**<br>**Care**<br>**Providers** |<br>**Patients**<br>**Served** |
| **De novo** | 146 | 445 | 111400 | —% | 4.5% | 17.1% |
| **Wholly-owned** | 204 | 874 | 304900 | 23.5% | 18.6% | 20.1% |
| **Independent Physician Associations** |  |  | 74800 |  |  | 40.1% |
| **Total** | 350 | 1319 | 491100 | 13.7% | 13.9% | 22.5% |

---

(1) Includes 54 primary care centers and approximately 59,000 patients associated with the acquisition of MaxHealth, which closed in February 2026.

(2) Includes 8 primary care centers and approximately 32,000 patients associated with the acquisition of The Villages Health, which closed in November 2025.

------

**Humana Inc.**

**Footnotes to Statistical Schedules and Supplementary Information**

**1Q26 Earnings Release** 

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;A.Net losses associated with the company's non-consolidated minority interest investments.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;B.The 2026 group Medicare Advantage and stand-alone PDP membership totals reflect the impact of certain of the company's group Medicare Advantage contracts decoupling its beneficiaries' Medicare Part D prescription drug coverage from the related medical coverage via the group Medicare Advantage plan. This impacts approximately 350,000 members which appear in both the group Medicare Advantage and stand-alone PDP membership ending membership balances as of March 31, 2026. The financial impact for the Part D prescription drug coverage of these members is reflected only in the Medicare stand-alone PDP results while their medical coverage is included within the group Medicare Advantage results.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;C.Beginning in 2026, members enrolled in a highly integrated dual eligible (HIDE) or fully integrated dual eligible (FIDE) special needs plan (SNP) are considered aligned dual eligibles, and as such, are simultaneously included in the company's state-based contracts membership, as well as in a dual eligible special need plan (DSNP) which is included as part of the individual Medicare Advantage membership. For these members, Humana receives premium revenue from both the respective states with the HIDE and FIDE SNP contracts and from CMS to cover the distinctly different benefits managed.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;D.Fully-insured dental membership as reported does not include Humana members that have a Medicare Advantage plan that includes an embedded dental benefit.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;E.In certain circumstances, the company contracts with providers to accept financial risk for a defined set of Medicare Advantage membership. For these Downside Risk arrangements, the provider is measured against a medical expense ratio target and the company may share savings from reduction to the total cost of care of the defined membership. The result is a high level of engagement on the part of the provider. Under these arrangements, the company may contract with providers to accept partial, full, or global financial risk. In certain instances (capitated shared risk) of these arrangements, the company may choose to prepay these providers a monthly fixed-fee per member to coordinate substantially all of the medical care for their Medicare Advantage members assigned or attributed to their provider panel, including some health benefit administrative functions and claims processing.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;F.A Path to Risk provider is one who has a high level of engagement and has contracted with the company to participate in an Upside Only/Shared Savings total cost of care arrangement and/or in one of Humana's Quality Bonus programs (Model Practice), through which the company rewards the provider for achieving quality and utilization targets. Providers who are contracted in an Upside Only/Shared Savings arrangement may receive a portion of achieved surpluses when the actual cost of the medical services provided to patients assigned or attributed to their panel is less than the agreed upon medical expense targets. These contracts may also include a Downside Risk trigger (future date or membership threshold) which has not yet been met.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;G.Per Member per Month (PMPM) shown reflects only Medicaid premiums and average Medicaid membership for the period. The 2025 period includes the impact of dual eligible demonstration members; all dual eligible demonstration programs sunset at the end of 2025.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;H.Specialty per member per month is computed based on reported specialty premiums and average fully-insured specialty membership for the period.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;I.The amounts primarily reflect services revenues under the TRICARE East Region contract that generally are contracted on a per-member basis.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;J.Computed based on average membership for the period (i.e. monthly ending membership during the period divided by the number of months in the period).

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;K.Reflects patient admissions under the Patient Driven Groupings Model (PDGM) payment model.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;L.Reflects all patient admissions regardless of reimbursement model. Same store is defined as care centers that have been owned and operated at least the last twelve months and startups that are an expansion of a same store care center, net of the impact of the consolidation of care centers that occurred during the last twelve months.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;M.*De novo* refers to all new centers opened or acquired since 2020 under a Welsh, Carson, Anderson & Stowe (WCAS) joint venture*. Wholly-owned* refers to all centers outside a WCAS joint venture.

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;N.Represents Medicare Advantage (MA) risk, MA path to risk, MA value-based, Direct Contracting Entity, and Accountable Care Organization patients.

## Exhibit 99.3

***&nbsp;&nbsp;&nbsp;&nbsp;*Exhibit 99.3 &nbsp;&nbsp;&nbsp;&nbsp;**

**Humana Inc. First Quarter 2026 Prepared Management Remarks 4/29/2026**

![image_0.jpg](image_0.jpg)

Please view these remarks in conjunction with our 1Q 2026 earnings release that can be found on our website at www.humana.com under the Investors section, or via the following link: https://humana.gcs-web.com/financial-information/quarterly-results.

We also invite you to listen to our live question and answer webcast with our President and Chief Executive Officer, Jim Rechtin, Chief Financial Officer, Celeste Mellet, President of Insurance, George Renaudin, and President of CenterWell, Dr. Sanjay Shetty, which will begin today at 8:00 a.m. Eastern Time and will be available via the following link: https://humana.gcs-web.com/events-and-presentations/upcoming-events. For those unable to listen to the live event, the archive will be available in the Historical Webcasts and Presentations section of the Investor Relations page via the following link: https://humana.gcs-web.com/events-and-presentations.

**<u>Cautionary Statement</u>**

Certain of the matters discussed in these prepared remarks are forward-looking and are subject to a number of risks, uncertainties and assumptions. Actual results could differ materially.

Investors are advised to read the detailed risk factors discussed in our latest Form 10-K, our other filings with the Securities and Exchange Commission, and our 1Q 2026 earnings release as they relate to forward-looking statements along with other risks discussed in our SEC filings. We undertake no obligation to publicly address or update any forward-looking statements in future filings or communications regarding our business or results.

Today's release, our historical financial news releases and our filings with the SEC are all also available on our Investor Relations site.

These remarks include financial measures that are not in accordance with generally accepted accounting principles, or GAAP.

Management's explanation for the use of these non-GAAP measures and reconciliations of GAAP to non-GAAP financial measures are included in today's release which can be found via the following link: https://humana.gcs-web.com/financial-information/quarterly-results.

Finally, any references to earnings per share or EPS made within these remarks refer to diluted earnings per common share.

------

***&nbsp;&nbsp;&nbsp;&nbsp;*Exhibit 99.3 &nbsp;&nbsp;&nbsp;&nbsp;**

**Humana Inc. First Quarter 2026 Prepared Management Remarks 4/29/2026**

**<u>Key Messages</u>**

• **Pleased with a solid start to 2026**, reporting 1Q26 Adjusted Earnings Per Share (EPS) of $10.31, at the high end of our guidance range of 110% to 115% of expected full year (FY) 2026 Adjusted EPS

o**Delivered strong 1Q26 Insurance segment results** with membership and revenue, including member risk scores, tracking in line with expectations and our Insurance segment benefit ratio of 89.4%, slightly favorable to our guidance of 'just under 90%'

While it remains early, **available information to date suggests that medical and pharmacy cost trends are slightly better than our expectations**, across both new and existing membership

o**1Q26 CenterWell segment results reflect solid growth across each line of business** driven by Humana membership growth and continued agnostic expansion

Results in the quarter include certain timing impacts, as well as the transaction and integration costs associated with the MaxHealth acquisition which were not previously included in guidance due to the timing of deal close

o**1Q26 Adjusted consolidated operating cost ratio of 10.0% and Insurance Segment operating cost ratio of 7.3%**, represent a 50 basis point (bps) and 90 bps reduction year over year, respectively

Reduction driven by operating leverage from membership and revenue growth, along with tactical cost cutting and transformation efforts, which remain on track

• **Based on results to date, we affirmed our FY 2026 guidance, including:**

oAdjusted EPS outlook of 'at least $9.00'

oInsurance segment & CenterWell segment income from operations

oInsurance segment benefit ratio guidance of 92.75%, plus or minus 25 bps, and consolidated operating cost ratio of 10.0%, plus or minus 25 bps

oMedicare and Medicaid membership growth expectations

• **We continue to strategically expand our CenterWell and Medicaid platforms, including:**

o1Q26 patient growth of approximately 110,500, or over 22%, in CenterWell Primary Care

oCenterWell Pharmacy and Cost Plus are partnering to develop new, end-to-end employer prescription solutions

o1Q26 Medicaid member growth of approximately 50,000, driven by the start of programs in Michigan, Illinois and South Carolina

• **Efforts to strengthen our Stars program continue to progress as anticipated** as we **focus on achieving Top Quartile Stars results in Bonus Year (BY) 2028**

• Looking ahead to 2027, **the Final MA Rate Notice meaningfully improved over the preliminary rate notice**, and **we appreciate CMS for their engagement throughout the process**

oHowever, we continue to see a persistent gap between the Final MA Rate Notice and medical cost trend, and **will adjust benefits as necessary to ensure we remain on track to deliver a stable and compelling MA margin**

• All in, we **believe our expanded membership base, relentless focus on returning to Top Quartile Stars results, and continued pricing discipline position us well to deliver a stable and compelling MA margin and unlock the earnings potential of the business by 2028** as laid out at our 2025 Investor Day

------

***&nbsp;&nbsp;&nbsp;&nbsp;*Exhibit 99.3 &nbsp;&nbsp;&nbsp;&nbsp;**

**Humana Inc. First Quarter 2026 Prepared Management Remarks 4/29/2026**

***Detailed Discussion:***

**Insurance**

Delivered strong 1Q26 Insurance segment results with membership and revenue, including member risk scores, tracking in line with expectations and our Insurance segment benefit ratio of 89.4%, slightly favorable to our guidance of 'just under 90%'. While it remains early, available information to date suggests that medical and pharmacy cost trends are slightly better than our expectations, across both new and existing membership.

*<u>Individual MA</u>*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 1Q26 year to date (YTD) membership increase of approximately 1,144,000, or 22%, is tracking in line with our FY 2026 expectation of approximately 25% membership growth

oMembership increases driven by new sales and improved retention from our customer-led benefit strategy and changes to our customer service approach

oYTD growth represents a higher than historical percentage of expected FY growth due to the previously discussed adjustments made to our post-Annual Election Period (AEP) and Open Enrollment Period (OEP) marketing and distribution strategies, which are driving the intended result

We will continue to manage our marketing and distribution strategies dynamically

oRemain confident we have the operational capacity to deliver an exceptional experience and high-quality care that improves member retention, inclusive of our new Stars onboarding initiatives

oMembership growth expected to further fuel our ability to unlock the earnings potential of the business by 2028 as laid out at our 2025 Investor Day

*<u>Group MA</u>*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 1Q26 YTD membership growth of approximately 161,000 is in line with expectations; we continue to anticipate approximately 150,000 member growth for FY 2026

*<u>Individual Stand-Alone Part D (PDP)</u>*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 1Q26 YTD membership growth of approximately 1,053,000 is tracking in line with our FY 2026 expectation of approximately 1 million member growth

o2026 membership growth is largely concentrated in our Basic and Value PDP plans

*<u>Medicaid</u>*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• 1Q26 YTD membership growth of approximately 50,000 is in line with expectations; we continue to anticipate 25,000 to 100,000 member growth for FY 2026, representing an increase of approximately 4% for the year at the midpoint

oYTD member growth largely driven by the January 1st initial phase-in of the Michigan Highly Integrated Dual Eligible (HIDE) Special Need Plan (SNP), the statewide Illinois Fully Integrated Dual Eligible (FIDE) SNP program launch, as well as the carve in of dual eligibles into the South Carolina Medicaid program

------

***&nbsp;&nbsp;&nbsp;&nbsp;*Exhibit 99.3 &nbsp;&nbsp;&nbsp;&nbsp;**

**Humana Inc. First Quarter 2026 Prepared Management Remarks 4/29/2026**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Continue to navigate procurement challenges related to our recent awards in Texas and Georgia. We remain bullish on these awards and our ability to win new business and successfully deliver value for our members and state partners

oCurrently anticipate a decision on our Illinois Temporary Assistance for Needy Families (TANF) Request for Proposal (RFP) submission in the second quarter of 2026

**CenterWell**

1Q26 CenterWell results reflect solid growth across each line of business driven by Humana membership growth and continued agnostic expansion. Results in the quarter reflect certain timing impacts, as well as the transaction and integration costs associated with the MaxHealth acquisition which were not previously included in guidance due to the timing of deal close.

*<u>Primary Care</u>*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Serving approximately 601,600 patients as of March 31, 2026, an increase of 110,500 patients, or over 22%, from December 31, 2025. Patient growth for the first quarter includes:

o19,100 patients, or 17% growth, in our de novo centers

o61,400 patients, or 20% growth, in our more mature wholly-owned centers; and

o30,000 patients, or 40%, growth in our Independent Physician Associations (IPA) business

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Aiding this patient growth is improved patient satisfaction, which increased Net Promoter Score (NPS) 200 basis points year over year

oImprovement supported by national, market and clinic level activities to enhance the new patient onboarding journey and drive increased patient utilization of the Electronic Medical Record (EMR) portal &nbsp;&nbsp;&nbsp;&nbsp;

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Operating 398 centers as of March 31, 2026, representing growth of 69 centers, or 21%, year over year, while representing an increase of 48 centers, or 14%, from December 31, 2025

oThe year over year and sequential increase in centers is largely driven by recently completed acquisitions, including The Villages Health (4Q25) and MaxHealth (1Q26)

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We still anticipate we will mitigate the ultimate impact of the v28 risk model changes over the three-year phase in through a multi-pronged plan including numerous operational efficiencies such as centralizing and streamlining administrative functions, standardizing the clinic operating model, and improving clinician productivity to increase capacity

oThe impact of v28 and our related mitigation efforts are tracking in line with expectations to date

------

***&nbsp;&nbsp;&nbsp;&nbsp;*Exhibit 99.3 &nbsp;&nbsp;&nbsp;&nbsp;**

**Humana Inc. First Quarter 2026 Prepared Management Remarks 4/29/2026**

*<u>Home</u>*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Within our CenterWell Home Health fee-for-service business, 1Q26 same store admissions grew approximately 4% year over year; consistent with our expectation of a mid-single digit increase in home health admissions for FY 2026

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• OneHome successfully launched the next phase of its Skilled Nursing Facility (SNF) value-based care model, increasing total coverage by approximately 2 million lives across 15 states during 1Q26

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Our comprehensive initiative to drive productivity and efficiency within our home operating model to offset reimbursement and other pressures is driving the intended results

*<u>Pharmacy</u>*

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• CenterWell Pharmacy drove strong results in 1Q26 with increased year over year volumes driven by:

oHumana's membership growth and continued industry leading mail order penetration

oContinued expansion of our agnostic client base with a significant year over year increase in Specialty, Direct to Consumer, and Direct to Employer volumes

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Finally, we are pleased that Cost Plus has recently selected CenterWell Pharmacy as a pharmacy partner and Cost Plus Drugs' digital pharmacy SaaS solution, SwiftyRx, will be used by CenterWell pharmacy creating an end to end solution to simplify medication access and lower patient cost

**Earnings Seasonality**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We expect second quarter earnings to be approximately 80% to 85% of expected FY 2026 Adjusted earnings

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Second quarter Insurance segment benefit ratio expected to be slightly above 91% and we expect the consolidated benefit ratio will be generally in line with the Insurance segment benefit ratio

**Capital Deployment & Balance Sheet**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We have made significant progress on our efforts to increase the efficiency of our balance sheet and fortify our foundation, including:

oBolstering liquidity and addressing future funding needs with ratings agency friendly instruments

Upsizing to a 5-Year, $5 billion Revolving Credit Facility during 2025

$1 billion Junior Subordinated Notes offering completed in March 2026 which is expected to fund 2027 maturities and attracts equity and capital credit at rating agencies

------

***&nbsp;&nbsp;&nbsp;&nbsp;*Exhibit 99.3 &nbsp;&nbsp;&nbsp;&nbsp;**

**Humana Inc. First Quarter 2026 Prepared Management Remarks 4/29/2026**

oExecuting several initiatives to drive balance sheet efficiency, including subsidiary reinsurance and optimizing legal entity structures, successfully mitigating approximately $3.2 billion in capital contribution requirements for 2026

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We have also maintained a prudent capital deployment approach, including:

oPursuing non-core asset divestitures to help fund strategic acquisitions

oMaintaining our dividend flat year over year on a per share basis throughout 2026

oLimiting share repurchases to the amount necessary to offset dilution related to the issuance of employee stock compensation

oMaintaining our debt to capitalization ratio near our long-term target of approximately 40%

As of March 31, 2026, our debt to capitalization ratio is 43%, up 190 bps from 41.1% at December 31, 2025 reflective of the company's $1.0 billion public offering announced in March 2026, partially offset by the impact of the 1Q26 net earnings

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• All in, our capital efficiency efforts are delivering results, and are our capital levels provide a prudent buffer above regulatory and rating agency requirements

oConsistent with this disciplined approach, we continue to evaluate a pipeline of initiatives to further strengthen the balance sheet

**Conclusion**

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We had a solid start to 2026 and remain confident in our FY 2026 guidance

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• We remain focused on levers within our control, driving clinical excellence and improved operating efficiency, which we expect to drive better health outcomes and experiences for our members, patients, provider partners and associates, while delivering compelling long-term value for our shareholders

&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;• Finally, we believe our expanded membership base, relentless focus on returning to Top Quartile Stars results, and continued pricing discipline position us well to deliver a stable and compelling MA margin and unlock the earnings potential of the business by 2028 as laid out at our 2025 Investor Day

<br>